GoodRx is a compelling small-cap value play with stabilizing growth, expanding pharma partnerships, and potential acquisition ...

As public health data becomes harder to access, journalists and experts at AHCJ25 shared tips and tools for uncovering and ...

GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the launch of GoodRx ...

Insurance challenges leave millions of Americans frustrated when trying to fill prescriptions. The bureaucratic obstacles not only exacerbate delays, but often translate to more of the cost burden ...

We recently published a list of Jim Cramer’s Thoughts on These 12 Stocks. In this article, we are going to take a look at ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on GoodRx Holdings GDRX ... This supplementary information provides further guidance for ...

GoodRx reported Q1 revenue of $203M, beating estimates and lifting full-year EBITDA guidance. J.P. Morgan maintained a $7 price target, citing margin strength and pharma revenue growth. Ready to ...

Get the annual and quarterly balance sheet of GoodRx Holdings, Inc. (GDRX) including details of assets, liabilities and shareholders' equity.

GoodRx reaffirmed its full-year 2025 revenue outlook of $810-$840 million and raised its adjusted EBITDA forecast to $273–$287 million, compared to $260.2 million in 2024.